Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis

Abstract

The SC administration of eight weekly doses of efalizumab improves signs and symptoms of psoriasis. The treatment was safe and very well tolerated. In comparison to previously published results with IV efalizumab, SC administration of efalizumab improves overall safety and tolerability, with the additional advantage of greater convenience.